Maximus - MMS Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Maximus in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MMS shares.
View MMS analyst ratings or view top-rated stocks.

1 equities research analysts have issued twelve-month target prices for Maximus' shares. Their MMS share price forecasts range from $100.00 to $100.00. On average, they predict the company's stock price to reach $100.00 in the next twelve months. This suggests a possible upside of 30.4% from the stock's current price.
View analysts price targets for MMS or view top-rated stocks among Wall Street analysts.

Maximus' stock was trading at $73.33 at the start of the year. Since then, MMS stock has increased by 4.6% and is now trading at $76.67.
View the best growth stocks for 2023 here.

Maximus saw a decline in short interest in the month of February. As of February 28th, there was short interest totaling 1,300,000 shares, a decline of 23.5% from the February 13th total of 1,700,000 shares. Based on an average daily volume of 400,800 shares, the short-interest ratio is presently 3.2 days. Currently, 2.2% of the company's shares are sold short.
View Maximus' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our MMS earnings forecast.

Maximus, Inc. (NYSE:MMS) issued its earnings results on Wednesday, February, 8th. The health services provider reported $0.94 EPS for the quarter, beating analysts' consensus estimates of $0.79 by $0.15. The health services provider earned $1.25 billion during the quarter, compared to the consensus estimate of $1.15 billion. Maximus had a trailing twelve-month return on equity of 16.64% and a net margin of 4.03%. Maximus's quarterly revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.12 EPS.

Maximus announced a quarterly dividend on Tuesday, January 10th. Stockholders of record on Wednesday, February 15th will be paid a dividend of $0.28 per share on Tuesday, February 28th. This represents a $1.12 annualized dividend and a dividend yield of 1.46%. The ex-dividend date is Tuesday, February 14th.
Read our dividend analysis for MMS.

ETFs with the largest weight of Maximus (NYSE:MMS) stock in their portfolio include Formidable Fortress ETF (KONG), Fidelity Digital Health ETF (FDHT), ALPS O'Shares U.S. Small-Cap Quality Dividend ETF (OUSM), iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV), Fidelity Low Volatility Factor ETF (FDLO), Pacer Lunt MidCap Multi-Factor Alternator ETF (PAMC), SPDR SSGA US Small Cap Low Volatility Index ETF (SMLV) and Fidelity Blue Chip Value ETF (FBCV).

Maximus (NYSE:MMS) pays an annual dividend of $1.12 per share and currently has a dividend yield of 1.51%. The dividend payout ratio is 36.25%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MMS will have a dividend payout ratio of 23.83% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MMS.

Maximus updated its FY 2023 earnings guidance on Friday, February, 10th. The company provided earnings per share (EPS) guidance of $4.00-$4.30 for the period, compared to the consensus estimate of $3.82. The company issued revenue guidance of $4.85 billion-$5.00 billion, compared to the consensus revenue estimate of $4.77 billion.

145 employees have rated Maximus Chief Executive Officer Bruce Caswell on Glassdoor.com. Bruce Caswell has an approval rating of 80% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Maximus investors own include Pfizer (PFE), Lennar (LEN), AbbVie (ABBV), Cisco Systems (CSCO), Kroger (KR), Skyworks Solutions (SWKS), Advanced Micro Devices (AMD), Cerner (CERN), Intel (INTC) and JD.com (JD).

Maximus trades on the New York Stock Exchange (NYSE) under the ticker symbol "MMS."

Maximus' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (11.09%), Victory Capital Management Inc. (11.09%), Fuller & Thaler Asset Management Inc. (4.76%), Alliancebernstein L.P. (4.62%), Mackenzie Financial Corp (4.51%) and Geode Capital Management LLC (2.00%). Insiders that own company stock include Bruce Caswell, David Francis, David Mutryn, Ilene R Baylinson, Michelle F Link, Peter Pond, Raymond B Ruddy, Richard A Montoni, Richard A Montoni, Richard John Nadeau, Teresa Weipert, Thomas D Romeo and Thomas D Romeo.
View institutional ownership trends.

Shares of MMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MMS stock can currently be purchased for approximately $76.67.

Maximus (NYSE:MMS) has a market capitalization of $4.66 billion and generates $4.63 billion in revenue each year. The health services provider earns $203.83 million in net income (profit) each year or $3.09 on an earnings per share basis.

The company employs 39,500 workers across the globe.

Maximus' mailing address is 1891 METRO CENTER DRIVE, RESTON VA, 20190. The official website for the company is www.maximus.com. The health services provider can be reached via phone at (703) 251-8500, via email at investorrelations@maximus.com, or via fax at 703-251-8240.